Needham sees H2 2015 approval for Acadia's pimavanserin in PDP

|By:, SA News Editor

Sentiment turns sour on Acadia Pharmaceuticals (ACAD -4.7%) following Tuesday's Q2 report.

Undeterred is Needham's Alan Carr who lifts his price target on the shares to $26 (from $16) citing a likely H2 2015 approval for pimavanserin in Parkinson's Disease Psychosis.